Arcturus Therapeutics (NASDAQ:ARCT) Posts Earnings Results

Arcturus Therapeutics (NASDAQ:ARCT) posted its earnings results on Thursday. The biotechnology company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.08, FiscalAI reports. Arcturus Therapeutics had a negative return on equity of 35.25% and a negative net margin of 143.80%.The firm had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• Arcturus has begun enrollment in a 12-week open?label Phase II of ARCT?032 for Class 1 cystic fibrosis and reports patients have tolerated continuous inhaled dosing beyond one month, which the company attributes to its proprietary LUNAR delivery lipids and mRNA purification process.
• After a Type C meeting with the FDA, ARCT?810 (OTC deficiency) received clear regulatory direction toward a pivotal pediatric development path; Arcturus is collecting additional exploratory data and plans an end?of?Phase II meeting in H2 2026.
• Financially, Arcturus reported $213.4 million in cash as of March 31, 2026 and says its cash runway extends beyond Q2 2028 following cost reductions and a strategic refocus on rare disease programs, despite a year?over?year revenue decline tied to reduced collaboration income.
• Partner Meiji is actively manufacturing Arcturus’ self?amplifying mRNA COVID vaccine KOSTAIVE for Japan’s 2026/2027 season and will provide all commercial guidance, leaving Arcturus’ near?term commercial exposure dependent on the partner.

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT traded up $0.32 during midday trading on Friday, hitting $9.22. The company had a trading volume of 933,138 shares, compared to its average volume of 341,200. The company has a market cap of $262.03 million, a price-to-earnings ratio of -3.28 and a beta of 2.43. Arcturus Therapeutics has a 12-month low of $5.85 and a 12-month high of $24.17. The company has a fifty day moving average of $7.89 and a two-hundred day moving average of $7.83.

Institutional Investors Weigh In On Arcturus Therapeutics

Institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new stake in shares of Arcturus Therapeutics during the fourth quarter valued at approximately $210,000. Panagora Asset Management Inc. purchased a new position in Arcturus Therapeutics during the fourth quarter valued at approximately $213,000. Aristides Capital LLC purchased a new position in Arcturus Therapeutics during the fourth quarter valued at approximately $161,000. Alps Advisors Inc. increased its holdings in Arcturus Therapeutics by 78.0% during the fourth quarter. Alps Advisors Inc. now owns 23,325 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 10,224 shares during the period. Finally, CANADA LIFE ASSURANCE Co increased its holdings in Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,567 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ARCT shares. Roth Mkm assumed coverage on Arcturus Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price target on the stock. Citigroup lowered their price objective on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. B. Riley Financial began coverage on Arcturus Therapeutics in a report on Wednesday, March 18th. They set a “buy” rating and a $22.00 price target on the stock. Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st. Finally, Piper Sandler lowered their price target on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.